Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 02, 2008. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Capital Structure Details
- Issued Share Capital (as of May 30, 2008): 5,830,641,767 Ordinary shares of 25p each.
- Treasury Shares: 484,194,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,346,447,609.
Material Changes and Outlook
The filing text does not provide a clear value for material changes versus prior periods, guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the calculation of voting rights for shareholder notification purposes.
Investor Verification Points
- Verify the total number of voting rights (5,346,447,609) to determine notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (484,194,158) which are excluded from the voting rights count.
- Note that this filing does not contain operational or financial performance updates.